Interestingly, she said, since the hindbrain GLP-1 neurons do not express GLP-1 receptors, they cannot be accessed directly by systemically administered GLP-1R agonists
While this pharmacology underlies therapeutic benefit in obesity and T2D, it simultaneously establishes conditions of persistently reduced nutrient inflow
GLP-1 Medications with a simple generic name of "semaglutide", "liraglutide", "tirzepatide", "dulaglutide", "exenatide", "exenatide microspheres", or "insulin degludec/liraglutide" and at least one of: A pharmaceutical class of "ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST" or "ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION" A pharmaceutical class that contains "GLP-1" A pharmaceutical subclass that contains the text "GLP-1"
Off-label prescribing is legal, common, and based on clinician judgment and available evidence